A Study of Sabroxy™ (Oroxylum Indicum Extract) for Improving Cognitive Function in Adults With Mild Memory Concerns

This is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of Sabroxy™ (Oroxylum indicum extract) on cognitive function in adults with self-reported, mild cognitive impairment. Approximately 84 participants will be recruited, with a goal of 80 completing the study. Participants will be between 60-85 years old, in generally good health, and living independently. Eligible participants must report concerns about their memory or thinking, confirmed with a screening test (MoCA). After screening and baseline assessments, participants will be randomly assigned to receive either Sabroxy™ or placebo. Both products will look identical to ensure blinding. Participants will take one capsule twice daily, after meals, for 12 weeks. The study assessments include: Computerized Mental Performance Assessment (COMPASS): tests of memory, attention, and reaction time. Montreal Cognitive Assessment (MoCA): an interviewer-administered cognitive test. Mild Cognitive Impairment Questionnaire: a self-reported measure of memory and thinking concerns. Blood samples: to measure Brain-Derived Neurotrophic Factor (BDNF) at baseline and week 12. Daily diaries and capsule counts: to monitor adherence. The visit schedule is as follows: Baseline (Visit 1): Screening, informed consent, eligibility check, cognitive testing, blood draw, product distribution, and diary instructions. Week 4 (Visit 2): Product count, diary review, questionnaire. Week 8 (Visit 3): Product count, diary review, questionnaire. Week 12 (Visit 4): Cognitive testing, blood draw, questionnaire, product return, diary review. Statistical analyses will compare changes in cognitive performance and BDNF levels between the Sabroxy™ and placebo groups. This study will provide important information about the potential of Sabroxy™ to support memory and brain health in older adults with mild cognitive concerns.